{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:25:14Z","timestamp":1770290714330,"version":"3.49.0"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science Research and Innovation","award":["B01F650006, BCG.659 and B05F650041"],"award-info":[{"award-number":["B01F650006, BCG.659 and B05F650041"]}]},{"name":"Faculty of Medicine Ramathibodi hospital, Mahidol University"},{"name":"Scholarships for Ph.D. Students from Mahidol University"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Cisplatin is a widely used chemotherapeutic drug for various cancers. One of the common adverse effects of cisplatin is nephrotoxicity including acute kidney injury (AKI) and acute kidney disease (AKD). Single Nucleotide Polymorphisms (SNPs) can be used to identify cancer patients who are susceptible to developing cisplatin-induced nephrotoxicity (CIN). In this study, we validated the association between 6 SNPs in the drug metabolizing enzyme genes, <jats:italic>SLC22A2<\/jats:italic> (rs316019) &amp; <jats:italic>EPHX1<\/jats:italic> (rs1051740), and the DNA repair genes, <jats:italic>ERCC1<\/jats:italic> (rs11615 &amp; rs3212986) &amp; <jats:italic>ERCC2<\/jats:italic> (rs13181 &amp; rs1799793), and CIN in the 169 Thai patients with head and neck, lung, or esophageal cancer. Effect of these SNPs on cumulative incidence of AKD, progression-free survival (PFS), and overall survival (OS) was also assessed. <jats:italic>EPHX1<\/jats:italic> rs1051740 TC genotype was significantly associated with AKD in co-dominant [OR 2.894, 95% CI 1.091\u20137.680; <jats:italic>P<\/jats:italic>\u2009=\u20090.033] and over-dominant [OR 2.793, 95% CI 1.333\u20135.851; <jats:italic>P<\/jats:italic>\u2009=\u20090.006] models, and with an increased cumulative incidence of AKD (<jats:italic>P<\/jats:italic>\u2009=\u20090.021). Additionally, <jats:italic>ERCC2<\/jats:italic> rs13181 and rs1799793 were significantly associated with OS (<jats:italic>P<\/jats:italic>\u2009=\u20090.002 and 0.004). Our results reveal an association between <jats:italic>EPHX1<\/jats:italic> rs1051740 and AKD, and confirms the previously reported associations between <jats:italic>ERCC2<\/jats:italic> SNPs and OS. These findings may help in predicting CIN in Thai cancer patients.<\/jats:p>","DOI":"10.1371\/journal.pone.0324699","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T17:26:14Z","timestamp":1750181174000},"page":"e0324699","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["EPHX1 and ERCC2 polymorphisms are associated with cisplatin-induced nephrotoxicity and prognosis in Thai cancer patients"],"prefix":"10.1371","volume":"20","author":[{"given":"Saad","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8060-9566","authenticated-orcid":true,"given":"Jakris","family":"Eu-ahsunthornwattana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanaporn","family":"Thamrongjirapat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruchalean","family":"Taweewongsounton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutthana","family":"Rittavee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7780-606X","authenticated-orcid":true,"given":"Nintita Sripaiboonkit","family":"Thokanit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montien","family":"Ngodngamthaweesuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pitichote","family":"Hiranyatheb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanyanan","family":"Reungwetwattana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuttapong","family":"Ngamphaiboon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3437-4698","authenticated-orcid":true,"given":"Natini","family":"Jinawath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"issue":"2","key":"pone.0324699.ref001","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00520-020-05566-y","article-title":"Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin","volume":"29","author":"T Patimarattananan","year":"2021","journal-title":"Support Care Cancer"},{"issue":"9209","key":"pone.0324699.ref002","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(00)02044-4","article-title":"Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer","volume":"355","author":"JA Gietema","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"pone.0324699.ref003","first-page":"1619","article-title":"Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study","volume":"35","author":"LV Hjelle","year":"2015","journal-title":"Anticancer Res"},{"key":"pone.0324699.ref004","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3389\/fphar.2018.01111","article-title":"Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review","volume":"9","author":"Z Zazuli","year":"2018","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0324699.ref005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","article-title":"Cisplatin nephrotoxicity: a review of the literature","volume":"31","author":"S Manohar","year":"2018","journal-title":"J Nephrol"},{"issue":"2","key":"pone.0324699.ref006","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41397-018-0014-8","article-title":"Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients","volume":"19","author":"C P\u00e9rez-Ram\u00edrez","year":"2019","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"pone.0324699.ref007","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0002-9343(78)90825-2","article-title":"Platinum nephrotoxicity","volume":"65","author":"NE Madias","year":"1978","journal-title":"Am J Med"},{"issue":"11","key":"pone.0324699.ref008","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of Cisplatin nephrotoxicity","volume":"2","author":"RP Miller","year":"2010","journal-title":"Toxins (Basel)"},{"issue":"1","key":"pone.0324699.ref009","article-title":"The influence of acute kidney disease on the clinical outcomes of patients who received cisplatin, carboplatin, and oxaliplatin","volume":"5","author":"ARDS Fernandes","year":"2022","journal-title":"Health Sci Rep"},{"issue":"11","key":"pone.0324699.ref010","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1007\/s10147-020-01755-1","article-title":"Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study","volume":"25","author":"T Hase","year":"2020","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"pone.0324699.ref011","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijrobp.2022.07.007","article-title":"A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II\/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study)","volume":"114","author":"H Takeuchi","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"pone.0324699.ref012","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.21.01293","article-title":"Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II\/III Randomized Controlled Trial","volume":"40","author":"N Kiyota","year":"2022","journal-title":"J Clin Oncol"},{"key":"pone.0324699.ref013","doi-asserted-by":"crossref","first-page":"10527","DOI":"10.2147\/IJGM.S343644","article-title":"Correlation between higher cumulative dose of cisplatin for concurrent chemoradiation and acute kidney disease incidence among nasopharyngeal carcinoma patients: A comparative study","volume":"14","author":"A Rachman","year":"2021","journal-title":"Int J Gen Med"},{"issue":"1","key":"pone.0324699.ref014","first-page":"1","article-title":"Kdigo clinical practice guideline for acute kidney injury","volume":"2","author":"JA Kellum","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"pone.0324699.ref015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2217\/pgs.13.237","article-title":"Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer","volume":"15","author":"AV Khrunin","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"4","key":"pone.0324699.ref016","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3390\/cancers11040551","article-title":"Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study)","volume":"11","author":"CM Driessen","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"5","key":"pone.0324699.ref017","doi-asserted-by":"crossref","DOI":"10.3390\/genes10050364","article-title":"Outcome definition influences the relationship between genetic polymorphisms of ERCC1, ERCC2, SLC22A2 and cisplatin nephrotoxicity in adult testicular cancer patients","volume":"10","author":"Z Zazuli","year":"2019","journal-title":"Genes"},{"issue":"4","key":"pone.0324699.ref018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123347","article-title":"Systematic Review and Meta-Analysis of the Relationship between EPHX1 Polymorphisms and the Risk of Head and Neck Cancer","volume":"10","author":"H Chen","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"pone.0324699.ref019","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12032-017-0905-6","article-title":"Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems","volume":"34","author":"Y Xiong","year":"2017","journal-title":"Med Oncol"},{"issue":"1","key":"pone.0324699.ref020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s13054-016-1478-z","article-title":"Acute kidney injury 2016: diagnosis and diagnostic workup","volume":"20","author":"M Ostermann","year":"2016","journal-title":"Crit Care"},{"issue":"4","key":"pone.0324699.ref021","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/clpt.2009.139","article-title":"Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity","volume":"86","author":"KK Filipski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"pone.0324699.ref022","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-012-0638-y","article-title":"Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events","volume":"16","author":"K Iwata","year":"2012","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"pone.0324699.ref023","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.fct.2012.03.077","article-title":"Ameliorative effects of SLC22A2 gene polymorphism 808 G\/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients","volume":"50","author":"J Zhang","year":"2012","journal-title":"Food Chem Toxicol"},{"issue":"7","key":"pone.0324699.ref024","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071333","article-title":"Pharmacogenomic variants may influence the urinary excretion of novel kidney injury biomarkers in patients receiving cisplatin","volume":"18","author":"C Chang","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0324699.ref025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/tpj.2009.45","article-title":"Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients","volume":"10","author":"AV Khrunin","year":"2010","journal-title":"Pharmacogenomics J"},{"issue":"10","key":"pone.0324699.ref026","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2217\/pgs.11.93","article-title":"Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms","volume":"12","author":"MV Tzvetkov","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"17","key":"pone.0324699.ref027","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2008.19.1718","article-title":"Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie","volume":"27","author":"E Goekkurt","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0324699.ref028","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12094-015-1343-6","article-title":"The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients","volume":"18","author":"T Powr\u00f3zek","year":"2016","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"pone.0324699.ref029","doi-asserted-by":"crossref","first-page":"16190","DOI":"10.18632\/oncotarget.7668","article-title":"XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation","volume":"8","author":"L Lopes-Aguiar","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"pone.0324699.ref030","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/cge.14060","article-title":"The Thai reference exome (T-REx) variant database","volume":"100","author":"V Shotelersuk","year":"2021","journal-title":"Clin Genet"},{"issue":"4","key":"pone.0324699.ref031","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrneph.2017.2","article-title":"Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup","volume":"13","author":"LS Chawla","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"pone.0324699.ref032","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.kint.2021.06.028","article-title":"Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference","volume":"100","author":"NH Lameire","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"pone.0324699.ref033","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000516647","article-title":"Defining AKD: The Spectrum of AKI, AKD, and CKD","volume":"146","author":"AS Levey","year":"2022","journal-title":"Nephron"},{"key":"pone.0324699.ref034","doi-asserted-by":"crossref","first-page":"101760","DOI":"10.1016\/j.eclinm.2022.101760","article-title":"Outcomes associated with acute kidney disease: A systematic review and meta-analysis","volume":"55","author":"CC Su","year":"2023","journal-title":"EClinicalMedicine"},{"key":"pone.0324699.ref035","doi-asserted-by":"crossref","first-page":"101291","DOI":"10.1016\/j.eclinm.2022.101291","article-title":"Short- and long-term outcomes of intensive care patients with acute kidney disease","volume":"44","author":"M Andonovic","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"1","key":"pone.0324699.ref036","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1757-2215-6-40","article-title":"mEH Tyr113His polymorphism and the risk of ovarian cancer development","volume":"6","author":"J-H Zhong","year":"2013","journal-title":"J Ovarian Res"},{"issue":"3","key":"pone.0324699.ref037","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/hmg\/3.3.421","article-title":"Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants","volume":"3","author":"C Hassett","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"8","key":"pone.0324699.ref038","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/j.1440-1746.2010.06354.x","article-title":"Role of epoxide hydrolase 1 gene polymorphisms in esophageal cancer in a high-risk area in India","volume":"25","author":"R Ihsan","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"pone.0324699.ref039","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3748\/wjg.v9.i12.2654","article-title":"Epoxide hydrolase Tyr113His polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma in population of North China","volume":"9","author":"J Zhang","year":"2003","journal-title":"World J Gastroenterol"},{"issue":"2","key":"pone.0324699.ref040","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.canlet.2005.06.010","article-title":"The association between microsomal epoxide hydrolase genotypes and esophageal squamous-cell-carcinoma in Taiwan: interaction between areca chewing and smoking","volume":"237","author":"Y-C Lin","year":"2006","journal-title":"Cancer Lett"},{"issue":"10","key":"pone.0324699.ref041","first-page":"17941","article-title":"Association between EPHX1 rs1051740 and lung cancer susceptibility: a meta-analysis","volume":"8","author":"P Zhang","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"2","key":"pone.0324699.ref042","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s13277-012-0644-4","article-title":"Association between microsomal epoxide hydrolase 1 T113C polymorphism and susceptibility to lung cancer","volume":"34","author":"S Wang","year":"2013","journal-title":"Tumour Biol"},{"issue":"6","key":"pone.0324699.ref043","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/07357907.2011.587070","article-title":"Association of functionally important polymorphism of microsomal epoxide hydrolase gene (EPHX1) with lung cancer susceptibility","volume":"29","author":"AR Tilak","year":"2011","journal-title":"Cancer Invest"},{"issue":"8","key":"pone.0324699.ref044","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1158\/1055-9965.EPI-10-1165","article-title":"Genetically lowered microsomal epoxide hydrolase activity and tobacco-related cancer in 47,000 individuals","volume":"20","author":"J Lee","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"pone.0324699.ref045","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrg3051","article-title":"Understanding the contribution of synonymous mutations to human disease","volume":"12","author":"ZE Sauna","year":"2011","journal-title":"Nat Rev Genet"},{"issue":"2","key":"pone.0324699.ref046","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijheh.2010.01.004","article-title":"Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients","volume":"213","author":"S Chen","year":"2010","journal-title":"Int J Hyg Environ Health"},{"issue":"7","key":"pone.0324699.ref047","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/cncr.26472","article-title":"Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study","volume":"118","author":"RE Windsor","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"pone.0324699.ref048","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.lungcan.2012.04.016","article-title":"Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy","volume":"77","author":"S-H Kim","year":"2012","journal-title":"Lung Cancer"},{"issue":"3","key":"pone.0324699.ref049","article-title":"Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients","volume":"7","author":"W Wu","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"pone.0324699.ref050","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1007\/s13277-013-1493-5","article-title":"The association between the ERCC1\/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis","volume":"35","author":"Y Yang","year":"2014","journal-title":"Tumour Biol"},{"issue":"9","key":"pone.0324699.ref051","article-title":"ERCC1 and ERCC2 variants predict survival in gastric cancer patients","volume":"8","author":"Y Li","year":"2013","journal-title":"PLoS One"},{"key":"pone.0324699.ref052","first-page":"359","article-title":"The Association of Single-Nucleotide Polymorphism rs13181 in ERCC2 with Risk and Prognosis of Nasopharyngeal Carcinoma in an Endemic Chinese Population","volume":"14","author":"Z Wei","year":"2021","journal-title":"Pharmgenomics Pers Med"},{"issue":"1","key":"pone.0324699.ref053","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41397-020-0174-1","article-title":"ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy","volume":"21","author":"M Guberina","year":"2021","journal-title":"Pharmacogenomics J"},{"issue":"10","key":"pone.0324699.ref054","first-page":"6941","article-title":"Effect of ERCC2 rs13181 and rs1799793 polymorphisms and environmental factors on the prognosis of patients with lung cancer","volume":"12","author":"H Zhang","year":"2020","journal-title":"Am J Transl Res"},{"issue":"5","key":"pone.0324699.ref055","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.21037\/jtd-21-755","article-title":"The association between the ERCC1\/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer","volume":"13","author":"C Jiang","year":"2021","journal-title":"J Thorac Dis"},{"key":"pone.0324699.ref056","doi-asserted-by":"crossref","first-page":"106520","DOI":"10.1016\/j.oraloncology.2023.106520","article-title":"Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma","volume":"145","author":"N Ngamphaiboon","year":"2023","journal-title":"Oral Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T17:26:35Z","timestamp":1750181195000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324699"}},"subtitle":[],"editor":[{"given":"Milad","family":"Khorasani","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324699","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}